



Corrigendum: Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier

OPEN ACCESS

Approved by:
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

***Correspondence:**
Giovanni Barbara
giovanni.barbara@unibo.it

Specialty section:
This article was submitted to
Nutritional Immunology,
a section of the journal
Frontiers in Nutrition

Received: 06 October 2021

Accepted: 07 October 2021

Published: 01 November 2021

Citation:
Barbara G, Barbaro MR, Fuschi D,
Palombo M, Falangone F, Cremon C,
Marasco G and Stanghellini V (2021)
Corrigendum: Inflammatory and
Microbiota-Related Regulation of the
Intestinal Epithelial Barrier.
Front. Nutr. 8:790387.
doi: 10.3389/fnut.2021.790387

Giovanni Barbara^{1,2*}, Maria Raffaella Barbaro^{1,2}, Daniele Fuschi^{1,2}, Marta Palombo^{1,2},
Francesca Falangone³, Cesare Cremon^{1,2}, Giovanni Marasco^{1,2} and
Vincenzo Stanghellini^{1,2}

¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ² Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, ³ Medical-Surgical Department of Clinical Sciences and Translational Medicine, University Sapienza, Rome, Italy

Keywords: intestinal epithelial barrier, mucosal immune system, gut microbiota, IBS, IBD, celiac disease, non-celiac gluten sensitivity

A Corrigendum on

Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier

by Barbara, G., Barbaro, M. R., Fuschi, D., Palombo, M., Falangone, F., Cremon, C., Marasco, G., and Stanghellini, V. (2021). *Front. Nutr.* 8:718356. doi: 10.3389/fnut.2021.718356

Incorrect Reference

In the original article, there is a mistake in the references cited in the text. From reference 105 onwards, the number does not correspond to the correct citation. The corrected references appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

REFERENCES

- Turner JR. Intestinal mucosal barrier function in health and disease. *Nat Rev Immunol.* (2009) 9:799–809. doi: 10.1038/nri2653
- Helander HF, Fändriks L. Surface area of the digestive tract-revisited. *Scand J Gastroenterol.* (2014) 49:681–9. doi: 10.3109/00365521.2014.898326
- Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. *Gut.* (2019) 68:1516–26. doi: 10.1136/gutjnl-2019-318427
- Yen TH, Wright NA. The gastrointestinal tract stem cell niche. *Stem Cell Rev.* (2006) 2:203–12. doi: 10.1007/s12015-006-0048-1
- Von Moltke J, Ji M, Liang HE, Locksley RM. Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit. *Nature.* (2016) 529:221–5. doi: 10.1038/nature16161
- Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, et al. Intestinal permeability - a new target for disease prevention and therapy. *BMC Gastroenterol.* (2014) 14:189. doi: 10.1186/s12876-014-0189-7
- Salvo-Romero E, Alonso-Cotoner C, Pardo-Camacho C, Casado-Bedmar M, Vicario M. The intestinal barrier function and its involvement in digestive disease. *Rev Esp Enfermedades Dig.* (2015) 107:686–96. doi: 10.17235/reed.2015.3846/2015
- Meddings J. The significance of the gut barrier in disease. *Gut.* (2008) 57:438–40. doi: 10.1136/gut.2007.143172
- Hansson GC. Mucus and mucins in diseases of the intestinal and respiratory tracts. *J Intern Med.* (2019) 285:479–90. doi: 10.1111/joim.12910
- Gillois K, Lévêque M, Théodorou V, Robert H, Mercier-Bonin M. Mucus: an underestimated gut target for environmental pollutants and food additives. *Microorganisms.* (2018) 6:53. doi: 10.3390/microorganisms6020053
- Johansson MEV, Hansson GC. Immunological aspects of intestinal mucus and mucins. *Nat Rev Immunol.* (2016) 16:639–49. doi: 10.1038/nri.2016.88
- Cone RA. Barrier properties of mucus. *Adv Drug Deliv Rev.* (2009) 61:75–85. doi: 10.1016/j.addr.2008.09.008
- König J, Wells J, Cani PD, García-Ródenas CL, MacDonald T, Mercenier A, et al. Human intestinal barrier function in health and disease. *Clin Transl Gastroenterol.* (2016) 7:e196. doi: 10.1038/ctg.2016.54
- Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. *Curr Gastroenterol Rep.* (2010) 12:319–30. doi: 10.1007/s11894-010-0131-2
- Hansson GC. Mucins and the Microbiome. *Annu Rev Biochem.* (2020) 89:769–93. doi: 10.1146/annurev-biochem-011520-105053
- Bansil R, Turner BS. The biology of mucus: composition, synthesis and organization. *Adv Drug Deliv Rev.* (2018) 124:3–15. doi: 10.1016/j.addr.2017.09.023
- LAMONT JT. Mucus: the front line of intestinal mucosal defense. *Ann N Y Acad Sci.* (1992) 664:190–201. doi: 10.1111/j.1749-6632.1992.tb39760.x
- Kim JJ, Khan WI. Goblet cells and mucins: role in innate defense in enteric infections. *Pathogens.* (2013) 2:55–70. doi: 10.3390/pathogens2010055
- Strugnell RA, Wijburg OLC. The role of secretory antibodies in infection immunity. *Nat Rev Microbiol.* (2010) 8:656–67. doi: 10.1038/nrmicro2384
- Huus KE, Petersen C, Finlay BB. Diversity and dynamism of IgA-microbiota interactions. *Nat Rev Immunol.* (2021) 21:514–25. doi: 10.1038/s41577-021-00506-1
- Pelaseyed T, Hansson GC. Membrane mucins of the intestine at a glance. *J Cell Sci.* (2020) 133:jcs240929. doi: 10.1242/JCS.240929
- Etienne-Mesmin L, Chassaing B, Desvaux M, De Paep K, Gresse R, Sauvatre T, et al. Experimental models to study intestinal microbes-mucus interactions in health and disease. *FEMS Microbiol Rev.* (2019) 43:457–89. doi: 10.1093/femsre/fuz013
- Pelaseyed T, Bergström JH, Gustafsson JK, Ermund A, Birchenough GMH, Schütte A, et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. *Immunol Rev.* (2014) 260:8–20. doi: 10.1111/imr.12182
- Pabst O, Mowat AM. Oral tolerance to food protein. *Mucosal Immunol.* (2012) 5:232–9. doi: 10.1038/mi.2012.4
- Shan M, Gentile M, Yeiser JR, Walland AC, Bornstein VU, Chen K, et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. *Science.* (2013) 342:447–53. doi: 10.1126/science.1237910
- Ermund A, Gustafsson JK, Hansson GC, Keita Å V. Mucus properties and goblet cell quantification in mouse, rat and human ileal Peyer's patches. *PLoS ONE.* (2013) 8:e83688. doi: 10.1371/journal.pone.0083688
- Johansson MEV, Holmén Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. *Proc Natl Acad Sci USA.* (2011) 108:4659–65. doi: 10.1073/pnas.1006451107
- Atuma C, Strugala V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state *in vivo.* *Am J Physiol Gastrointest Liver Physiol.* (2001) 280:G922–9. doi: 10.1152/ajpgi.2001.280.5.g922
- Ermund A, Schütte A, Johansson MEV, Gustafsson JK, Hansson GC. Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer's patches. *Am J Physiol Gastrointest Liver Physiol.* (2013) 305:G341–7. doi: 10.1152/ajpgi.00046.2013
- Birchenough GMH, Johansson MEV, Gustafsson JK, Bergström JH, Hansson GC. New developments in goblet cell mucus secretion and function. *Mucosal Immunol.* (2015) 8:712–9. doi: 10.1038/mi.2015.32
- Ouellette AJ. Paneth cells and innate mucosal immunity. *Curr Opin Gastroenterol.* (2010) 26:547–53. doi: 10.1097/MOG.0b013e32833dcde
- Heazlewood CK, Cook MC, Eri R, Price GR, Tauro SB, Taupin D, et al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. *PLoS Med.* (2008) 5:54. doi: 10.1371/journal.pmed.0050054
- Renner M, Bergmann G, Krebs I, End C, Lyer S, Hilberg F, et al. DMBT1 confers mucosal protection *in vivo* and a deletion variant is associated with Crohn's disease. *Gastroenterology.* (2007) 133:1499–509. doi: 10.1053/j.gastro.2007.08.007
- Hooper LV, MacPherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. *Nat Rev Immunol.* (2010) 10:159–69. doi: 10.1038/nri2710
- Meyer-Hoffert U, Hornef MW, Henriques-Normark B, Axelsson LG, Midtvedt T, Pütsep K, et al. Secreted enteric antimicrobial activity localises to the mucus surface layer. *Gut.* (2008) 57:764–71. doi: 10.1136/gut.2007.141481
- Van Der Waaij LA, Harmsen HJM, Madjipour M, Kroese FGM, Zwiens M, Van Dullemen HM, et al. Bacterial population analysis of human colon and terminal ileum biopsies with 16S rRNA-based fluorescent probes: commensal bacteria live in suspension and have no direct contact with epithelial cells. *Inflamm Bowel Dis.* (2005) 11:865–71. doi: 10.1097/01.mib.0000179212.80778.d3
- Johansson MEV, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. *Proc Natl Acad Sci USA.* (2008) 105:15064–9. doi: 10.1073/pnas.0803124105
- Johansson MEV, Sjövall H, Hansson GC. The gastrointestinal mucus system in health and disease. *Nat Rev Gastroenterol Hepatol.* (2013) 10:352–61. doi: 10.1038/nrgastro.2013.35
- Li H, Limenitakis JP, Fuhrer T, Geuking MB, Lawson MA, Wyss M, et al. The outer mucus layer hosts a distinct intestinal microbial niche. *Nat Commun.* (2015) 6:8292. doi: 10.1038/ncomms9292
- Kamphuis JBJ, Mercier-Bonin M, Eutamène H, Theodorou V. Mucus organisation is shaped by colonic content; a new view. *Sci Rep.* (2017) 7:8527. doi: 10.1038/s41598-017-08938-3
- Hoskins LC, Boulding ET. Mucin degradation in human colon ecosystems. *J Clin Invest.* (1981) 67:163–72. doi: 10.1172/jci110009
- Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment *in vitro* utilization of mucin by other bacteria. *Am J Gastroenterol.* (2010) 105:2420–8. doi: 10.1038/ajg.2010.281
- Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. *Cell.* (2016) 167:1339–53.e21. doi: 10.1016/j.cell.2016.10.043
- Johansson MEV, Jakobsson HE, Holmén-Larsson J, Schütte A, Ermund A, Rodríguez-Piñero AM, et al. Normalization of host intestinal mucus layers requires long-term microbial colonization. *Cell Host Microbe.* (2015) 18:582–92. doi: 10.1016/j.chom.2015.10.007

45. Schroeder BO. Fight them or feed them: how the intestinal mucus layer manages the gut microbiota. *Gastroenterol Rep.* (2019) 7:3–12. doi: 10.1093/gastro/goy052
46. Fu J, Wei B, Wen T, Johansson MEV, Liu X, Bradford E, et al. Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. *J Clin Invest.* (2011) 121:1657–66. doi: 10.1172/JCI45538
47. Larsson JMH, Karlsson H, Crespo JG, Johansson MEV, Eklund L, Sjövall H, et al. Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. *Inflamm Bowel Dis.* (2011) 17:2299–307. doi: 10.1002/ibd.21625
48. Johansson MEV, Gustafsson JK, Holmen-Larsson J, Jabbar KS, Xia L, Xu H, et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. *Gut.* (2014) 63:281–91. doi: 10.1136/gutjnl-2012-303207
49. Strugala V, Dettmar PW, Pearson JP. Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease. *Int J Clin Pract.* (2008) 62:762–9. doi: 10.1111/j.1742-1241.2007.01665.x
50. Pullan RD, Thomas GAO, Rhodes M, Newcombe RG, Williams GT, Allen A, et al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. *Gut.* (1994) 35:353–9. doi: 10.1136/gut.35.3.353
51. Buisine MP, Desreumaux P, Leteurtre E, Copin MC, Colombel JF, Porchet N, et al. Mucin gene expression in intestinal epithelial cells in Crohn's disease. *Gut.* (2001) 49:544–51. doi: 10.1136/gut.49.4.544
52. Buisine MP, Desreumaux P, Debailleul V, Gambiez L, Geboes K, Ectors N, et al. Abnormalities in mucin gene expression in Crohn's disease. *Inflamm Bowel Dis.* (1999) 5:24–32. doi: 10.1097/00054725-199902000-00004
53. Nakamori S, Ota DM, Cleary KR, Shirotani K, Irimura T. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. *Gastroenterology.* (1994) 106:353–61. doi: 10.1016/0016-5085(94)90592-4
54. Ajioka Y, Allison LJ, Jass JR. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. *J Clin Pathol.* (1996) 49:560–4. doi: 10.1136/jcp.49.7.560
55. McGuckin MA, Lindén SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. *Nat Rev Microbiol.* (2011) 9:265–78. doi: 10.1038/nrmicro2538
56. Dharmani P, Srivastava V, Kisooson-Singh V, Chadee K. Role of intestinal mucins in innate host defense mechanisms against pathogens. *J Innate Immun.* (2009) 1:123–35. doi: 10.1159/000163037
57. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. *Nature.* (2001) 410:1099–103. doi: 10.1038/35074106
58. Birchenough GMH, Nystrom EEL, Johansson MEV, Hansson GC. A sentinel goblet cell guards the colonic crypt by triggering Nlrp6-dependent Muc2 secretion. *Science.* (2016) 352:1535–42. doi: 10.1126/science.aaf7419
59. Wang S, Ahmadi S, Nagpal R, Jain S, Mishra SP, Kavanagh K, et al. Lipoteichoic acid from the cell wall of a heat killed *Lactobacillus paracasei* D3-5 ameliorates aging-related leaky gut, inflammation and improves physical and cognitive functions: from *C. elegans* to mice. *GeroScience.* (2020) 42:333–52. doi: 10.1007/s11357-019-00137-4
60. Lee KD, Guk SM, Chai JY. Toll-like receptor 2 and Muc2 expression on human intestinal epithelial cells by gymnopthalloides seoi adult antigen. *J Parasitol.* (2010) 96:58–66. doi: 10.1645/GE-2195.1
61. Kamdar K, Johnson AMF, Chac D, Myers K, Kulur V, Truevillan K, et al. Innate recognition of the microbiota by TLR1 promotes epithelial homeostasis and prevents chronic inflammation. *J Immunol.* (2018) 201:230–42. doi: 10.4049/jimmunol.1701216
62. Anderson JM, Van Itallie CM. Physiology and function of the tight junction. *Cold Spring Harb Perspect Biol.* (2009) 1:a002584. doi: 10.1101/cshperspect.a002584
63. Furuse M, Fujita K, Hiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. *J Cell Biol.* (1998) 141:1539–50. doi: 10.1083/jcb.141.7.1539
64. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, et al. Occludin: a novel integral membrane protein localizing at tight junctions. *J Cell Biol.* (1993) 123:1777–88. doi: 10.1083/jcb.123.6.1777
65. Martin-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. *J Cell Biol.* (1998) 142:117–27. doi: 10.1083/jcb.142.1.117
66. Ikenouchi J, Umeda K, Tsukita S, Furuse M, Tsukita S. Requirement of ZO-1 for the formation of belt-like adherens junctions during epithelial cell polarization. *J Cell Biol.* (2007) 176:779–86. doi: 10.1083/jcb.200612080
67. Günzel D, Fromm M. Claudins and other tight junction proteins. *Compr Physiol.* (2012) 2:1819–52. doi: 10.1002/cphy.c110045
68. Günzel D, Yu ASL. Claudins and the modulation of tight junction permeability. *Physiol Rev.* (2013) 93:525–69. doi: 10.1152/physrev.00019.2012
69. Suzuki T. Regulation of the intestinal barrier by nutrients: the role of tight junctions. *Anim Sci J.* (2020) 91:e13357. doi: 10.1111/asj.13357
70. Cong X, Kong W. Endothelial tight junctions and their regulatory signaling pathways in vascular homeostasis and disease. *Cell Signal.* (2020) 66:109485. doi: 10.1016/j.cellsig.2019.109485
71. Shen L, Weber CR, Raleigh DR, Yu D, Turner JR. Tight junction pore and leak pathways: a dynamic duo. *Annu Rev Physiol.* (2011) 73:283–309. doi: 10.1146/annurev-physiol-012110-142150
72. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. *Annu Rev Physiol.* (2006) 68:403–29. doi: 10.1146/annurev.physiol.68.040104.131404
73. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. *Gastroenterology.* (2005) 129:550–64. doi: 10.1016/j.gastro.2005.05.002
74. Ivanov AI, Nusrat A, Parkos CA. The epithelium in inflammatory bowel disease: potential role of endocytosis of junctional proteins in barrier disruption. *Novartis Found Symp.* (2004) 263:115–24. doi: 10.1002/0470090480.ch9
75. Kucharzik T, Walsh S V., Chen J, Parkos CA, Nusrat A. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. *Am J Pathol.* (2001) 159:2001–9. doi: 10.1016/S0002-9440(10)63051-9
76. Pizzuti D, Senzolo M, Buda A, Chiarelli S, Giacomelli L, Mazzon E, et al. *In vitro* model for IgE mediated food allergy. *Scand J Gastroenterol.* (2011) 46:177–87. doi: 10.3109/00365521.2010.525716
77. Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, Karatza E, Triantos C, Vagianos CE, et al. Altered intestinal tight junctions' expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. *Eur J Clin Invest.* (2012) 42:439–46. doi: 10.1111/j.1365-2362.2011.02609.x
78. Bertiaux-Vandaële N, Youmba SB, Belmonte L, Leclaire S, Antonietti M, Gourcerol G, et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. *Am J Gastroenterol.* (2011) 106:2165–73. doi: 10.1038/ajg.2011.257
79. Rahner C, Mitic LL, Anderson JM. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. *Gastroenterology.* (2001) 120:411–22. doi: 10.1053/gast.2001.21736
80. Reyes JL, Lamas M, Martin D, Namorado MDC, Islas S, Luna J, et al. The renal segmental distribution of claudins changes with development. *Kidney Int.* (2002) 62:476–87. doi: 10.1046/j.1523-1755.2002.00479.x
81. Wolburg H, Wolburg-Buchholz K, Liebner S, Engelhardt B. Claudin-1, claudin-2 and claudin-11 are present in tight junctions of choroid plexus epithelium of the mouse. *Neurosci Lett.* (2001) 307:77–80. doi: 10.1016/S0304-3940(01)01927-9
82. Zhu Y, Brännström M, Janson PO, Sundfeldt K. Differences in expression patterns of the tight junction proteins, claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. *Int J Cancer.* (2006) 118:1884–91. doi: 10.1002/ijc.21506
83. Oshima T, Miwa H, Joh T. Changes in the expression of claudins in active ulcerative colitis. *J Gastroenterol Hepatol.* (2008) 23:3–7. doi: 10.1111/j.1440-1746.2008.05405.x
84. Nagy Szakál D, Gyorffy H, Arató A, Cseh Á, Molnár K, Papp M, et al. Mucosal expression of claudins 2, 3 and 4 in proximal and distal part of

- duodenum in children with coeliac disease. *Virchows Arch.* (2010) 456:245–50. doi: 10.1007/s00428-009-0879-7
85. Martínez C, Lobo B, Pigrau M, Ramos L, González-Castro AM, Alonso C, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. *Gut.* (2013) 62:1160–8. doi: 10.1136/gutjnl-2012-302093
 86. Zeissig S, Bürgel N, Günzel D, Richter J, Mankertz J, Wahnschaffe U, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. *Gut.* (2007) 56:61–72. doi: 10.1136/gut.2006.094375
 87. Laurila JJ, Karttunen T, Koivukangas V, Laurila PA, Syrjälä H, Saarnio J, et al. Tight junction proteins in gallbladder epithelium: different expression in acute acalculous and calculous cholecystitis. *J Histochem Cytochem.* (2007) 55:567–73. doi: 10.1369/jhc.6A7155.2007
 88. Wolburg H, Wolburg-Buchholz K, Kraus J, Rascher-Eggstein G, Liebner S, Hamm S, et al. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. *Acta Neuropathol.* (2003) 105:586–92. doi: 10.1007/s00401-003-0688-z
 89. Kiuchi-Saishin Y, Gotoh S, Furuse M, Takasuga A, Tano Y, Tsukita S. Differential expression patterns of claudins, tight junction membrane proteins, in mouse nephron segments. *J Am Soc Nephrol.* (2002) 13:875–86. doi: 10.1681/asn.v134875
 90. Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. *Am J Physiol Gastrointest Liver Physiol.* (2009) 296:G1140–9. doi: 10.1152/ajpgi.90534.2008
 91. Oshima T, Miwa H. Gastrointestinal mucosal barrier function and diseases. *J Gastroenterol.* (2016) 51:768–78. doi: 10.1007/s00535-016-1207-z
 92. Sapone A, Lammers KM, Casolaro V, Cammarota M, Giuliano MT, De Rosa M, et al. Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: Celiac disease and gluten sensitivity. *BMC Med.* (2011) 9:23. doi: 10.1186/1741-7015-9-23
 93. Morita K, Sasaki H, Furuse M, Tsukita S. Endothelial claudin: Claudin-5/TM6CF constitutes tight junction strands in endothelial cells. *J Cell Biol.* (1999) 147:185–94. doi: 10.1083/jcb.147.1.185
 94. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. *J Cell Biol.* (2003) 161:653–60. doi: 10.1083/jcb.200302070
 95. Amasheh S, Schmidt T, Mahn M, Florian P, Mankertz J, Tavalali S, et al. Contribution of claudin-5 to barrier properties in tight junctions of epithelial cells. *Cell Tissue Res.* (2005) 321:89–96. doi: 10.1007/s00441-005-1101-0
 96. Schumann M, Günzel D, Bürgel N, Richter JF, Troeger H, May C, et al. Cell polarity-determining proteins Par-3 and PP-1 are involved in epithelial tight junction defects in coeliac disease. *Gut.* (2012) 61:220–8. doi: 10.1136/gutjnl-2011-300123
 97. Fujita H, Chiba H, Yokozaki H, Sakai N, Sugimoto K, Wada T, et al. Differential expression and subcellular localization of claudin-7, -8, -12, -13, and -15 along the mouse intestine. *J Histochem Cytochem.* (2006) 54:933–44. doi: 10.1369/jhc.6A6944.2006
 98. Go M, Kojima T, Takano KI, Murata M, Ichimiya S, Tsubota H, et al. Expression and function of tight junctions in the crypt epithelium of human palatine tonsils. *J Histochem Cytochem.* (2004) 52:1627–38. doi: 10.1369/jhc.4A6339.2004
 99. Li WY, Huey CL, Yu AS. Expression of claudin-7 and -8 along the mouse nephron. *Am J Physiol Renal Physiol.* (2004) 286:F1063–71. doi: 10.1152/ajprenal.00384.2003
 100. Turksen K, Troy TC. Claudin-6: a novel tight junction molecule is developmentally regulated in mouse embryonic epithelium. *Dev Dyn.* (2001) 222:292–300. doi: 10.1002/dvdy.1174
 101. Lameris AL, Huybers S, Kaukinen K, Mäkelä TH, Bindels RJ, Hoenderop JG, et al. Expression profiling of claudins in the human gastrointestinal tract in health and during inflammatory bowel disease. *Scand J Gastroenterol.* (2013) 48:58–69. doi: 10.3109/00365521.2012.741616
 102. Niimi T, Nagashima K, Ward JM, Minoo P, Zimonjic DB, Popescu NC, et al. claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. *Mol Cell Biol.* (2001) 21:7380–90. doi: 10.1128/mcb.21.21.7380-7390.2001
 103. Linares GR, Brommage R, Powell DR, Xing W, Chen ST, Alshbool FZ, et al. Claudin 18 is a novel negative regulator of bone resorption and osteoclast differentiation. *J Bone Miner Res.* (2012) 27:1553–65. doi: 10.1002/jbmr.1600
 104. Sanada Y, Oue N, Mitani Y, Yoshida K, Nakayama H, Yasui W. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. *J Pathol.* (2006) 208:633–42. doi: 10.1002/path.1922
 105. Wong V. Phosphorylation of occludin correlates with occludin localization and function at the tight junction. *Am J Physiol Cell Physiol.* (1997) 273:C1859–67. doi: 10.1152/ajpcell.1997.273.6.c1859
 106. Umeda K, Ikenouchi J, Katahira-Tayama S, Furuse K, Sasaki H, Nakayama M, et al. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. *Cell.* (2006) 126:741–54. doi: 10.1016/j.cell.2006.06.043
 107. González-Mariscal L, Quirós M, Díaz-Coránguez M. ZO proteins and redox-dependent processes. *Antioxidants Redox Signal.* (2011) 15:1235–53. doi: 10.1089/ars.2011.3913
 108. Jesaitis LA, Goodenough DA. Molecular characterization and tissue distribution of ZO-2, a tight junction protein homologous to ZO-1 and the *Drosophila* discs-large tumor suppressor protein. *J Cell Biol.* (1994) 124:949–61. doi: 10.1083/jcb.124.6.949
 109. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. *J Biol Chem.* (1998) 273:29745–53. doi: 10.1074/jbc.273.45.29745
 110. Itoh M, Morita K, Tsukita S. Characterization of ZO-2 as a MAGUK family member associated with tight as well as adherens junctions with a binding affinity to occludin and α catenin. *J Biol Chem.* (1999) 274:5981–6. doi: 10.1074/jbc.274.9.5981
 111. Fanning AS, Ma TY, Anderson JM. Isolation and functional characterization of the actin binding region in the tight junction protein ZO-1. *FASEB J.* (2002) 16:1835–7. doi: 10.1096/fj.02-0121fj
 112. Mandell KJ, Parkos CA. The JAM family of proteins. *Adv Drug Deliv Rev.* (2005) 57:857–67. doi: 10.1016/j.addr.2005.01.005
 113. Ebnet K. Junctional adhesion molecules (JAMs): cell adhesion receptors with pleiotropic functions in cell physiology and development. *Physiol Rev.* (2017) 97:1529–54. doi: 10.1152/physrev.00004.2017
 114. Van Itallie CM, Anderson JM. Architecture of tight junctions and principles of molecular composition. *Semin Cell Dev Biol.* (2014) 36:157–65. doi: 10.1016/j.semcdb.2014.08.011
 115. Laukoetter MG, Nava P, Lee WY, Severson EA, Capaldo CT, Babbitt BA, et al. JAM-A regulates permeability and inflammation in the intestine *in vivo*. *J Exp Med.* (2007) 204:3067–76. doi: 10.1084/jem.20071416
 116. Severson EA, Lee WY, Capaldo CT, Nusrat A, Parkos CA. Junctional adhesion molecule a interacts with afadin and PDZ-GEF2 to activate rap1A, regulate j31 integrin levels, and enhance cell migration. *Mol Biol Cell.* (2009) 20:1916–25. doi: 10.1091/mbc.E08-10-1014
 117. Nava P, Capaldo CT, Koch S, Kolegraf K, Rankin CR, Farkas AE, et al. JAM-A regulates epithelial proliferation through Akt/ β -catenin signalling. *EMBO Rep.* (2011) 12:314–20. doi: 10.1038/embor.2011.16
 118. Monteiro AC, Sumagin R, Rankin CR, Leoni G, Mina MJ, Reiter DM, et al. JAM-A associates with ZO-2, afadin, and PDZ-GEF1 to activate Rap2c and regulate epithelial barrier function. *Mol Biol Cell.* (2013) 24:2849–60. doi: 10.1091/mbc.E13-06-0298
 119. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JL. Increased intestinal permeability in patients with Crohn's disease and their relatives: a possible etiologic factor. *Ann Intern Med.* (1986) 105:883–5. doi: 10.7326/0003-4819-105-6-883
 120. Martínez C, Vicario M, Ramos L, Lobo B, Mosquera JL, Alonso C, et al. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. *Am J Gastroenterol.* (2012) 107:736–46. doi: 10.1038/ajg.2011.472
 121. Wilcz-Villega E, Mclean S, O'Sullivan M. Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of

- alternating and diarrhea predominant IBS. *Neurogastroenterol Motil.* (2014) 26:316–25. doi: 10.1111/nmo.12262
122. Drago S, El Asmar R, Di Pierro M, Clemente MG, Tripathi A, Sapone A, et al. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. *Scand J Gastroenterol.* (2006) 41:408–19. doi: 10.1080/00365520500235334
 123. Vetrano S, Rescigno M, Rosaria Cera M, Correale C, Rumio C, Doni A, et al. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory Bowel disease. *Gastroenterology.* (2008) 135:173–84. doi: 10.1053/j.gastro.2008.04.002
 124. Wilcz-Villega EM, McClean S, O'Sullivan MA. Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome. *Am J Gastroenterol.* (2013) 108:1140–51. doi: 10.1038/ajg.2013.92
 125. Cordenonsi M, D'Atri F, Hammar E, Parry DAD, Kendrick-Jones J, Shore D, et al. Cingulin contains globular and coiled-coil domains and interacts with ZO-1, ZO-2, ZO-3, and myosin. *J Cell Biol.* (1999) 147:1569–81. doi: 10.1083/jcb.147.7.1569
 126. Citi S, Paschoud S, Pulimeno P, Timolati F, De Robertis F, Jond L, et al. The tight junction protein cingulin regulates gene expression and rhoA signaling. *Ann N Y Acad Sci.* (2009) 1165:88–98. doi: 10.1111/j.1749-6632.2009.04053.x
 127. Suarez C, Kovar DR. Intenetwork competition for monomers governs actin cytoskeleton organization. *Nat Rev Mol Cell Biol.* (2016) 17:799–810. doi: 10.1038/nrm.2016.106
 128. Kim S, Coulombe PA. Emerging role for the cytoskeleton as an organizer and regulator of translation. *Nat Rev Mol Cell Biol.* (2010) 11:75–81. doi: 10.1038/nrm2818
 129. Al-Sadi RM, Ma TY. IL-1 β Causes an Increase in Intestinal Epithelial Tight Junction Permeability. *J Immunol.* (2007) 178:4641–9. doi: 10.4049/jimmunol.178.7.4641
 130. Schwayer C, Shamipour S, Pranjić-Ferscha K, Schauer A, Balda M, Tada M, et al. Mechanosensation of tight junctions depends on ZO-1 phase separation and flow. *Cell.* (2019) 179:937–52.e18. doi: 10.1016/j.cell.2019.10.006
 131. Holthöfer B, Windoffer R, Troyanovsky S, Leube RE. Structure and function of desmosomes. *Int Rev Cytol.* (2007) 264:65–163. doi: 10.1016/S0074-7696(07)64003-0
 132. Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. *Biochim Biophys Acta Biomembr.* (2008) 1778:660–9. doi: 10.1016/j.bbmem.2007.07.012
 133. Shapiro L, Weis WI. Structure and biochemistry of cadherins and catenins. *Cold Spring Harb Perspect Biol.* (2009) 1:a003053. doi: 10.1101/cshperspect.a003053
 134. Ivanov AI, Naydenov NG. Dynamics and regulation of epithelial adherens junctions. Recent discoveries and controversies. *Int Rev Cell Mol Biol.* (2013) 303:27–99. doi: 10.1016/B978-0-12-407697-6.00002-7
 135. Takeichi M. Dynamic contacts: rearranging adherens junctions to drive epithelial remodeling. *Nat Rev Mol Cell Biol.* (2014) 15:397–410. doi: 10.1038/nrm3802
 136. Nekrasova OE, Amargo EV, Smith WO, Chen J, Kreitzer GE, Green KJ. Desmosomal cadherins utilize distinct kinesins for assembly into desmosomes. *J Cell Biol.* (2011) 195:1185–203. doi: 10.1083/jcb.2011.06057
 137. Hatzfeld M, Keil R, Magin TM. Desmosomes and intermediate filaments: their consequences for tissue mechanics. *Cold Spring Harb Perspect Biol.* (2017) 9:a029157. doi: 10.1101/cshperspect.a029157
 138. Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzel-Arnett S, Buzza MS, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. *Proc Natl Acad Sci USA.* (2009) 106:16799–804. doi: 10.1073/pnas.0906773106
 139. Lammers KM, Lu R, Brownley J, Lu B, Gerard C, Thomas K, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. *Gastroenterology.* (2008) 135:194–204.e3. doi: 10.1053/j.gastro.2008.03.023
 140. Sapone A, De Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. *Diabetes.* (2006) 55:1443–9. doi: 10.2337/db05-1593
 141. Barbaro MR, Cremon C, Wrona D, Fuschi D, Marasco G, Stanghellini V, et al. Non-celiac gluten sensitivity in the context of functional gastrointestinal disorders. *Nutrients.* (2020) 12:1–21. doi: 10.3390/nu12123735
 142. Fasano A. Zonulin measurement conundrum: add confusion to confusion does not lead to clarity. *Gut.* (2020) 70:2007–8. doi: 10.1136/gutjnl-2020-323367
 143. Misra A. *Challenges in delivery of therapeutic genomics and proteomics.* Amsterdam: Elsevier Inc. (2011). doi: 10.1016/C2010-0-65663-X
 144. Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L, et al. Coexistence of passive and carrier-mediated processes in drug transport. *Nat Rev Drug Discov.* (2010) 9:597–614. doi: 10.1038/nrd3187
 145. Wang Y, DeMazumder D, Hill JA. Ionic fluxes and genesis of the cardiac action potential. *Muscle.* (2012) 1:67–85. doi: 10.1016/B978-0-12-381510-12-381510-7
 146. Horisberger JD, Chraïbi A. Epithelial sodium channel: a ligand-gated channel? *Nephron Physiol.* (2004) 96:37–41. doi: 10.1159/000076406
 147. Mukherjee B, Satapathy BS, Bhattacharya S, Chakraborty R, Mishra VP. Chapter 19 - Pharmacokinetic and pharmacodynamic modulations of therapeutically active constituents from orally administered nanocarriers along with a glimpse of their advantages and limitations. In: Grumezescu AM, editor. *Nano- and Microscale Drug Delivery Systems.* Elsevier. (2017). p. 357–75. doi: 10.1016/B978-0-323-52727-9.00019-4
 148. Goldstein JL, Anderson RGW, Brown MS. Coated pits, coated vesicles, and receptor-mediated endocytosis. *Nature.* (1979) 279:679–85. doi: 10.1038/279679a0
 149. Garcia-Castillo MD, Chinnapen DJF, Lencer WI. Membrane transport across polarized epithelia. *Cold Spring Harb Perspect Biol.* (2017) 9:a027912. doi: 10.1101/cshperspect.a027912
 150. Sandvig K, Kavaliuskiene S, Skotland T. Clathrin-independent endocytosis: an increasing degree of complexity. *Histochem Cell Biol.* (2018) 150:107–18. doi: 10.1007/s00418-018-1678-5
 151. Tuma PL, Hubbard AL. Transcytosis: crossing cellular barriers. *Physiol Rev.* (2003) 83:871–932. doi: 10.1152/physrev.00001.2003
 152. Mestecky J, Russell MW, Elson CO. Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. *Gut.* (1999) 44:2–5. doi: 10.1136/gut.44.1.2
 153. Kadaoui KA, Corthésy B. Secretory IgA mediates bacterial translocation to dendritic cells in mouse Peyer's patches with restriction to mucosal compartment. *J Immunol.* (2007) 179:7751–7. doi: 10.4049/jimmunol.179.11.7751
 154. Boullier S, Tanguy M, Kadaoui KA, Caubet C, Sansonetti P, Corthésy B, et al. Secretory IgA-mediated neutralization of *Shigella flexneri* prevents intestinal tissue destruction by down-regulating inflammatory circuits. *J Immunol.* (2009) 183:5879–85. doi: 10.4049/jimmunol.0901838
 155. Rey J, Garin N, Spertini F, Corthésy B. Targeting of secretory IgA to Peyer's patch dendritic and T cells after transport by intestinal M cells. *J Immunol.* (2004) 172:3026–33. doi: 10.4049/jimmunol.172.5.3026
 156. Matsiak-Budnik T, Moura IC, Arcos-Fajardo M, Lebreton C, Ménard S, Candalh C, et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. *J Exp Med.* (2008) 205:143–54. doi: 10.1084/jem.20071204
 157. Bevilacqua C, Montagnac G, Benmerah A, Candalh C, Brousse N, Cerf-Benusson N, et al. Food allergens are protected from degradation during CD23-mediated transepithelial transport. *Int Arch Allergy Immunol.* (2004) 205:143–54. doi: 10.1159/000080653
 158. Kaiserlian D, Lachaux A, Grosjean I, Graber P, Bonnefoy JY. Intestinal epithelial cells express the CD23/Fc ϵ R2 molecule: enhanced expression in enteropathies. *Immunology.* (1993) 80:90–5.
 159. Montagnac G, Yu LCH, Bevilacqua C, Heyman M, Conrad DH, Perdue MH, et al. Differential role for CD23 splice forms in apical to basolateral transcytosis of IgE/allergen complexes. *Traffic.* (2005) 6:230–42. doi: 10.1111/j.1600-0854.2005.00262.x
 160. Montagnac G, Mollà-Herman A, Bouchet J, Yu LCH, Conrad DH, Perdue MH, et al. Intracellular trafficking of CD23: differential regulation in humans and mice by both extracellular and intracellular exons. *J Immunol.* (2005) 174:5562–72. doi: 10.4049/jimmunol.174.9.5562
 161. Neal MD, Leapheart C, Levy R, Prince J, Billiar TR, Watkins S, et al. Enterocyte TLR4 Mediates Phagocytosis and Translocation of

- Bacteria Across the Intestinal Barrier. *J Immunol.* (2006) 176:3070–9. doi: 10.4049/jimmunol.176.5.3070
162. Conner SD, Schmid SL. Regulated portals of entry into the cell. *Nature.* (2003) 422:37–44. doi: 10.1038/nature01451
 163. Günther J, Seyfert HM. The first line of defence: insights into mechanisms and relevance of phagocytosis in epithelial cells. *Semin Immunopathol.* (2018) 40:555–65. doi: 10.1007/s00281-018-0701-1
 164. Hommelgaard AM, Roepstorff K, Vilhardt F, Torgersen ML, Sandvig K, van Deurs B. Caveolae: stable membrane domains with a potential for internalization. *Traffic.* (2005) 6:720–4. doi: 10.1111/j.1600-0854.2005.00314.x
 165. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature.* (2011) 474:298–306. doi: 10.1038/nature10208
 166. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature.* (2011) 474:307–17. doi: 10.1038/nature10209
 167. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. *Cell Mol Life Sci.* (2013) 70:631–59. doi: 10.1007/s00018-012-1070-x
 168. Berkes J, Viswanathan VK, Savkovic SD, Hecht G. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. *Gut.* (2003) 52:439–51. doi: 10.1136/gut.52.3.439
 169. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JL. Host-bacterial mutualism in the human intestine. *Science.* (2005) 307:1915–20. doi: 10.1126/science.1104816
 170. Hooper L V., Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science.* (2012) 336:1268–73. doi: 10.1126/science.1223490
 171. Kayama H, Okumura R, Takeda K. Interaction between the microbiota, epithelia, and immune cells in the intestine. *Annu Rev Immunol.* (2020) 38:23–48. doi: 10.1146/annurev-immunol-070119-115104
 172. Sonnenburg ED, Smits SA, Tikhonov M, Higginbottom SK, Wingreen NS, Sonnenburg JL. Diet-induced extinctions in the gut microbiota compound over generations. *Nature.* (2016) 529:212–5. doi: 10.1038/nature16504
 173. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. *Curr Opin Biotechnol.* (2013) 24:160–8. doi: 10.1016/j.copbio.2012.08.005
 174. Bäumlér AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. *Nature.* (2016) 535:85–93. doi: 10.1038/nature18849
 175. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. *Nat Rev Immunol.* (2013) 13:790–801. doi: 10.1038/nri3535
 176. Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. *Science.* (2016) 352:539–44. doi: 10.1126/science.aad9378
 177. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. *Nature.* (2016) 535:65–74. doi: 10.1038/nature18847
 178. Stecher B, Hardt WD. Mechanisms controlling pathogen colonization of the gut. *Curr Opin Microbiol.* (2011) 14:82–91. doi: 10.1016/j.mib.2010.10.003
 179. Keeney KM, Finlay BB. Enteric pathogen exploitation of the microbiota-generated nutrient environment of the gut. *Curr Opin Microbiol.* (2011) 14:92–8. doi: 10.1016/j.mib.2010.12.012
 180. Litvak Y, Byndloss MX, Bäumlér AJ. Colonocyte metabolism shapes the gut microbiota. *Science.* (2018) 362:eaat9076. doi: 10.1126/science.aat9076
 181. van Thiel IAM, de Jonge WJ, Chiu IM, van den Wijngaard RM. Microbiota-neuroimmune cross talk in stress-induced visceral hypersensitivity of the bowel. *Am J Physiol Gastrointest Liver Physiol.* (2020) 318:G1034–41. doi: 10.1152/ajpgi.00196.2019
 182. Chowdhury SR, King DE, Willing BP, Band MR, Beever JE, Lane AB, et al. Transcriptome profiling of the small intestinal epithelium in germfree versus conventional piglets. *BMC Genomics.* (2007) 8:215. doi: 10.1186/1471-2164-8-215
 183. Burger-van Paassen N, Vincent A, Puiman PJ, van der Sluis M, Bouma J, Boehm G, et al. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. *Biochem J.* (2009) 420:211–9. doi: 10.1042/BJ20082222
 184. Kim MH, Kang SG, Park JH, Yanagisawa M, Kim CH. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. *Gastroenterology.* (2013) 145:396–406.e1–10. doi: 10.1053/j.gastro.2013.04.056
 185. Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity.* (2014) 40:128–39. doi: 10.1016/j.immuni.2013.12.007
 186. Ghosh S, Whitley CS, Haribabu B, Jala VR. Regulation of intestinal barrier function by microbial. *Cell Mol Gastroenterol Hepatol.* (2021) 11:1463–82. doi: 10.1016/j.jcmgh.2021.02.007
 187. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. *Nat Rev Immunol.* (2010) 10:131–43. doi: 10.1038/nri2707
 188. Burgueño JF, Abreu MT. Epithelial Toll-like receptors and their role in gut homeostasis and disease. *Nat Rev Gastroenterol Hepatol.* (2020) 17:263–78. doi: 10.1038/s41575-019-0261-4
 189. Allam-Ndoul B, Castonguay-Paradis S, Veilleux A. Gut microbiota and intestinal trans-epithelial permeability. *Int J Mol Sci.* (2020) 21:1–14. doi: 10.3390/ijms21176402
 190. Hayes CL, Dong J, Galipeau HJ, Jury J, McCarville J, Huang X, et al. Commensal microbiota induces colonic barrier structure and functions that contribute to homeostasis. *Sci Rep.* (2018) 8:14184. doi: 10.1038/s41598-018-32366-6
 191. Hooper L V., Wong MH, Thelin A, Hansson L, Falk PG, Gordon JL. Molecular analysis of commensal host-microbial relationships in the intestine. *Science.* (2001) 291:881–4. doi: 10.1126/science.291.5505.881
 192. Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, et al. Probiotic *Escherichia coli* Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. *PLoS ONE.* (2007) 2:e1308. doi: 10.1371/journal.pone.0001308
 193. Barbaro MR, Fuschi D, Cremon C, Carapelle M, Dino P, Marcellini MM, et al. *Escherichia coli* Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators. *Neurogastroenterol Motil.* (2018) 30:e13388. doi: 10.1111/nmo.13388
 194. Johnson-Henry KC, Donato KA, Shen-Tu G, Gordanpour M, Sherman PM. *Lactobacillus rhamnosus* strain GG prevents enterohemorrhagic *Escherichia coli* O157:H7-induced changes in epithelial barrier function. *Infect Immun.* (2008) 76:1340–8. doi: 10.1128/IAI.00778-07
 195. Yu Q, Yuan L, Deng J, Yang Q. *Lactobacillus* protects the integrity of intestinal epithelial barrier damaged by pathogenic bacteria. *Front Cell Infect Microbiol.* (2015) 5:26. doi: 10.3389/fcimb.2015.00026
 196. Zareie M, Riff J, Donato K, McKay DM, Perdue MH, Soderholm JD, et al. Novel effects of the prototype translocating *Escherichia coli*, strain C25 on intestinal epithelial structure and barrier function. *Cell Microbiol.* (2005) 7:1782–97. doi: 10.1111/j.1462-5822.2005.00595.x
 197. Barbara G, Feinle-Bisset C, Ghoshal UC, Santos J, Vanner SJ, Vergnolle N, et al. The intestinal microenvironment and functional gastrointestinal disorders. *Gastroenterology.* (2016) 150:1305–18.e8. doi: 10.1053/j.gastro.2016.02.028
 198. Lee M, Chang EB. Inflammatory Bowel Diseases (IBD) and the microbiome—searching the crime scene for clues. *Gastroenterology.* (2021) 160:524–37. doi: 10.1053/j.gastro.2020.09.056
 199. Machiels K, Joossens M, Sabino J, De Preter V, Arijis I, Eeckhaut V, et al. A decrease of the butyrate-producing species *Roseburia hominis* and *Faecalibacterium prausnitzii* defines dysbiosis in patients with ulcerative colitis. *Gut.* (2014) 63:1275–83. doi: 10.1136/gutjnl-2013-304833
 200. Zhou L, Zhang M, Wang Y, Dorfman RG, Liu H, Yu T, et al. *Faecalibacterium prausnitzii* produces butyrate to maintain Th17/treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1. *Inflamm Bowel Dis.* (2018) 24:1926–40. doi: 10.1093/ibd/izy182
 201. Cremon C, Guglielmetti S, Gargari G, Taverniti V, Castellazzi AM, Valsecchi C, et al. Effect of *Lactobacillus paracasei* CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: a pilot randomized clinical trial. *United Eur Gastroenterol J.* (2018) 6:604–13. doi: 10.1177/2050640617736478

202. Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory Bowel disease. *Immunity*. (2019) 50:992–1006. doi: 10.1016/j.immuni.2019.03.017
203. Coccia M, Harrison OJ, Schiering C, Asquith MJ, Becher B, Powrie F, et al. IL-1 β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4 + Th17 cells. *J Exp Med*. (2012) 209:1595–609. doi: 10.1084/jem.20111453
204. Lee YS, Yang H, Yang JY, Kim Y, Lee SH, Kim JH, et al. Interleukin-1 (IL-1) signaling in intestinal stromal cells controls KC/ CXCL1 secretion, which correlates with recruitment of IL-22- secreting neutrophils at early stages of *Citrobacter rodentium* infection. *Infect Immun*. (2015) 83:3257–67. doi: 10.1128/IAI.00670-15
205. Song A, Zhu L, Gorantla G, Berdysz O, Amici SA, Guerau-De-Arellano M, et al. Salient type 1 interleukin 1 receptor expression in peripheral non-immune cells. *Sci Rep*. (2018) 8:723. doi: 10.1038/s41598-018-19248-7
206. Cox CB, Storm EE, Kapoor VN, Chavarria-Smith J, Lin DL, Wang L, et al. IL-1R1-dependent signaling coordinates epithelial regeneration in response to intestinal damage. *Sci Immunol*. (2021) 6:eabe8856. doi: 10.1126/sciimmunol.abe8856
207. Madara JL, Stafford J. Interferon- γ directly affects barrier function of cultured intestinal epithelial monolayers. *J Clin Invest*. (1989) 83:724–7. doi: 10.1172/JCI113938
208. Adams RB, Planchon SM, Roche JK. IFN-gamma modulation of epithelial barrier function. Time course, reversibility, and site of cytokine binding. *J Immunol*. (1993) 150:2356–63.
209. Schmitz H, Fromm M, Bentzel CJ, Scholz P, Detjen K, Mankertz J, et al. Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. *J Cell Sci*. (1999) 112(Pt 1):137–46.
210. Bruwer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. *J Immunol*. (2003) 171:6164–72. doi: 10.4049/jimmunol.171.11.6164
211. Barbaro MR, Di Sabatino A, Cremon C, Giuffrida P, Fiorentino M, Altimari A, et al. Interferon- γ is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. *Am J Physiol Gastrointest Liver Physiol*. (2016) 310:G439–47. doi: 10.1152/ajpgi.00368.2015
212. Zolotarevsky Y, Hecht G, Koutsouris A, Gonzalez DE, Quan C, Tom J, et al. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in *in vitro* models of intestinal disease. *Gastroenterology*. (2002) 123:163–72. doi: 10.1053/gast.2002.34235
213. Bhat AA, Uppada S, Achkar IW, Hashem S, Yadav SK, Shanmugakonar M, et al. Tight junction proteins and signaling pathways in cancer and inflammation: a functional crosstalk. *Front Physiol*. (2019) 10:1942. doi: 10.3389/fphys.2018.01942
214. Pham CTN. Neutrophil serine proteases: specific regulators of inflammation. *Nat Rev Immunol*. (2006) 6:541–50. doi: 10.1038/nri1841
215. Dale C, Vergnolle N. Protease signaling to G protein-coupled receptors: implications for inflammation and pain. *J Recept Signal Transduct*. (2008) 28:29–37. doi: 10.1080/10799890801941913
216. Chin AC, Lee WY, Nusrat A, Vergnolle N, Parkos CA. Neutrophil-mediated activation of epithelial protease-activated receptors-1 and-2 regulates barrier function and transepithelial migration. *J Immunol*. (2008) 181:5702–10. doi: 10.4049/jimmunol.181.8.5702
217. Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R. Functional gastrointestinal disorders and mast cells: implications for therapy. *Neurogastroenterol Motil*. (2006) 18:6–17. doi: 10.1111/j.1365-2982.2005.00685.x
218. Bashashati M, Moossavi S, Cremon C, Barbaro MR, Moraveji S, Talmon G, et al. Colonic immune cells in irritable bowel syndrome: a systematic review and meta-analysis. *Neurogastroenterol Motil*. (2018) 30:10. doi: 10.1111/nmo.13192
219. Bashashati M, Rezaei N, Shafieyoun A, McKernan DP, Chang L, Öhman L, Quigley EM, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. *Neurogastroenterol Motil*. (2014) 26:1036–48. doi: 10.1111/nmo.12358
220. Chang L, Adeyemo M, Karagiannidis I, Videlock EJ, Bowe C, Shih W, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. *Am J Gastroenterol*. (2012) 107:262–72. doi: 10.1038/ajg.2011.423
221. McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. *Aliment Pharmacol Ther*. (2011) 33:1045–52. doi: 10.1111/j.1365-2036.2011.04624.x
222. Darkoh C, Comer L, Zewdie G, Harold S, Snyder N, DuPont HL. Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome. *PLoS ONE*. (2014) 9:e93144. doi: 10.1371/journal.pone.0093144
223. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon- γ and tumor necrosis factor- α synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. *Am J Pathol*. (2005) 166:409–19. doi: 10.1016/S0002-9440(10)62264-X
224. Hanning N, Edwinston AL, Ceuleers H, Peters SA, De Man JG, Hassett LC, et al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. *Therap Adv Gastroenterol*. (2021) 14:1756284821993586. doi: 10.1177/1756284821993586
225. Renga G, Moretti S, Oikonomou V, Borghi M, Zelante T, Paolicelli G, et al. IL-9 and mast cells are key players of *Candida albicans* commensalism and pathogenesis in the gut. *Cell Rep*. (2018) 23:1767–78. doi: 10.1016/j.celrep.2018.04.034
226. Gerlach K, Hwang Y, Nikolaev A, Atreya R, Dornhoff H, Steiner S, et al. T H 9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. *Nat Immunol*. (2014) 15:676–86. doi: 10.1038/ni.2920
227. Gerlach K, McKenzie AN, Neurath MF, Weigmann B. IL-9 regulates intestinal barrier function in experimental T cell-mediated colitis. *Tissue Barriers*. (2015) 3:e983777. doi: 10.4161/21688370.2014.983777
228. Piche T, Barbara G, Aubert P, Des Varannes SB, Dainese R, Nano JL, et al. Impaired Intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. *Gut*. (2009) 185:196–201. doi: 10.1136/gut.2007.140806
229. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable Bowel syndrome. *Gastroenterology*. (2004) 126:693–702. doi: 10.1053/j.gastro.2003.11.055
230. Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable Bowel syndrome. *Gastroenterology*. (2007) 132:26–37. doi: 10.1053/j.gastro.2006.11.039
231. Gece K, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic luminal factor impairing colonic permeability and sensitivity. *Gut*. (2008) 57:591–8. doi: 10.1136/gut.2007.140210
232. Pontarollo G, Mann A, Brandão I, Malinarich F, Schöpf M, Reinhardt C. Protease-activated receptor signaling in intestinal permeability regulation. *FEBS J*. (2020) 287:645–58. doi: 10.1111/febs.15055
233. Barbara G, Grover M, Bercik P, Corsetti M, Ghoshal UC, Ohman L, et al. Rome foundation working team report on post-infection irritable Bowel syndrome. *Gastroenterology*. (2019) 156:46–58.e7. doi: 10.1053/j.gastro.2018.07.011
234. Edogawa S, Edwinston AL, Peters SA, Chikkamenahalli LL, Sundt W, Graves S, et al. Breen-Lyles M, Johnson S, Dyer R, et al. Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS. *Gut*. (2020) 69:62–73. doi: 10.1136/gutjnl-2018-317416
235. Cenac N, Bautzova T, Le Faouder P, Veldhuis NA, Poole DP, Rolland C, et al. Quantification and potential functions of endogenous agonists of transient receptor potential channels in patients with irritable bowel syndrome. *Gastroenterology*. (2015) 149:433–4.e7. doi: 10.1053/j.gastro.2015.04.011
236. Bautzova T, Hockley JRF, Perez-Berezo T, Pujo J, Tranter MM, Desormeaux C, et al. 5-oxoETE triggers nociception in constipation-predominant irritable bowel syndrome through MAS-related G protein-coupled receptor D. *Sci Signal*. (2018) 11:eaal2171. doi: 10.1126/scisignal.aal2171
237. Trifan A, Burta O, Tiuca N, Petrisor DC, Lenghel A, Santos J. Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: a randomised, crossover clinical trial. *United Eur Gastroenterol J*. (2019) 7:1093–101. doi: 10.1177/2050640619862721

238. Rubio-Tapia A, Murray JA. Updated guidelines by the European Society for the Study of Coeliac Disease. *United Eur Gastroenterol J.* (2019) 7:581–2. doi: 10.1177/2050640619849370
239. Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. *Gastroenterology.* (2009) 137:1912–33. doi: 10.1053/j.gastro.2009.09.008
240. Harris LA, Park JY, Voltaggio L, Lam-Himlin D. Celiac disease: clinical, endoscopic, and histopathologic review. *Gastrointest Endosc.* (2012) 76:625–40. doi: 10.1016/j.gie.2012.04.473
241. Greco L, Romino R, Coto I, Di Cosmo N, Percopo S, Maglio M, et al. The first large population based twin study of coeliac disease. *Gut.* (2002) 50:624–8. doi: 10.1136/gut.50.5.624
242. Caminero A, McCarville JL, Galipeau HJ, Deraison C, Bernier SP, Constante M, et al. Duodenal bacterial proteolytic activity determines sensitivity to dietary antigen through protease-activated receptor-2. *Nat Commun.* (2019) 10:1–14. doi: 10.1038/s41467-019-09037-9
243. Di Biase AR, Marasco G, Ravaoli F, Dajti E, Colecchia L, Righi B, et al. Gut microbiota signatures and clinical manifestations in celiac disease children at onset: a pilot study. *J Gastroenterol Hepatol.* (2020) 36:446–54. doi: 10.1111/jgh.15183
244. Marasco G, Ciota GG, Rossini B, Lungaro L, Di Biase AR, Colecchia A, et al. Probiotics, prebiotics and other dietary supplements for gut microbiota modulation in celiac disease patients. *Nutrients.* (2020) 12:2674. doi: 10.3390/nu12092674
245. Stene LC, Honeyman MC, Hoffenberg EJ, Haas JE, Sokol RJ, Emery L, et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. *Am J Gastroenterol.* (2006) 101:2333–40. doi: 10.1111/j.1572-0241.2006.00741.x
246. Zafeiropoulou K, Nichols B, Mackinder M, Biskou O, Rizou E, Karanikolou A, et al. Alterations in intestinal microbiota of children with celiac disease at time of diagnosis and on a gluten-free diet. *Gastroenterology.* (2020) 159:2039–51.e20. doi: 10.1053/j.gastro.2020.08.007
247. Marasco G, Di Biase AR, Colecchia A. Microbial signatures in celiac disease: still far from a final answer. *Gastroenterology.* (2020) 161:358–9. doi: 10.1053/j.gastro.2020.10.059
248. Marasco G, Di Biase AR, Schiumerini R, Eusebi LH, Iughetti L, Ravaoli F, et al. Gut microbiota and celiac disease. *Dig Dis Sci.* (2016) 61:1461–72. doi: 10.1007/s10620-015-4020-2
249. Jabri B, Abadie V. IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction. *Nat Rev Immunol.* (2015) 15:771–83. doi: 10.1038/nri3919
250. Catassi C, Elli L, Bonaz B, Bouma G, Carroccio A, Castillejo G, et al. Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): the Salerno experts' criteria. *Nutrients.* (2015) 7:4966–77. doi: 10.3390/nu7064966
251. Giovannini C, Sanchez M, Straface E, Scazzocchio B, Silano M, De Vincenzi M. Induction of apoptosis in Caco-2 cells by wheat gliadin peptides. *Toxicology.* (2000) 145:63–71. doi: 10.1016/S0300-483X(99)0223-1
252. Barone MV, Gimigliano A, Castoria G, Paoella G, Maurano F, Paparo F, et al. Growth factor-like activity of gliadin, an alimentary protein: implications for coeliac disease. *Gut.* (2007) 56:480–8. doi: 10.1136/gut.2005.086637
253. Heyman M, Abed J, Lebreton C, Cerf-Bensussan N. Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis. *Gut.* (2012) 61:1355–64. doi: 10.1136/gutjnl-2011-300327
254. Clemente MG, De Virgiliis S, Kang JS, Macatagney R, Musu MP, Di Pierro MR, et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. *Gut.* (2003) 52:218–23. doi: 10.1136/gut.52.2.218
255. Alaedini A, Latov N. Transglutaminase-independent binding of gliadin to intestinal brush border membrane and GM1 ganglioside. *J Neuroimmunol.* (2006) 177:167–72. doi: 10.1016/j.jneuroim.2006.04.022
256. Bondar C, Araya RE, Guzman L, Rua EC, Chopita N, Chirido FG. Role of CXCR3/CXCL10 axis in immune cell recruitment into the small intestine in celiac disease. *PLoS ONE.* (2014) 9:e0089068. doi: 10.1371/journal.pone.0089068
257. Careddu P, Chiumello G, Vaccari A, Bardare M, Zilocchi A. Effects of gluten on intestinal absorption and permeability during remission of celiac disease. *Boll Soc Ital Biol Sper.* (1963) 1963:1235–8.
258. Cobden I, Dickinson RJ, Rothwell J, Axon ATR. Intestinal permeability assessed by excretion ratios of two molecules: results in coeliac disease. *Br Med J.* (1978) 2:1060. doi: 10.1136/bmj.2.6144.1060
259. Oberhuber G, Vogelsang H. Gastrointestinal permeability in celiac disease [1]. *Gastroenterology.* (1998) 114:226. doi: 10.1016/S0016-5085(98)70661-4
260. Van Elburg RM, Uil JJ, Mulder CJJ, Heymans HSA. Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease. *Gut.* (1993) 34:354–7. doi: 10.1136/gut.34.3.354
261. Schulzke JD, Bentzel CJ, Schulzke I, Riecken EO, Fromm M. Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue. *Pediatr Res.* (1998) 43:435–41. doi: 10.1203/00006450-199804000-00001
262. Goswami P, Das P, Verma AK, Prakash S, Das TK, Nag TC, et al. Are alterations of tight junctions at molecular and ultrastructural level different in duodenal biopsies of patients with celiac disease and Crohn's disease? *Virchows Arch.* (2014) 465:521–30. doi: 10.1007/s00428-014-1651-1
263. Ciccocioppo R, Finamore A, Ara C, Di Sabatino A, Mengheri E, Corazza GR. Altered expression, localization, and phosphorylation of epithelial junctional proteins in celiac disease. *Am J Clin Pathol.* (2006) 125:502–11. doi: 10.1309/dtyr-a91g-8r0k-tm8m
264. Montalto M, Cuoco L, Ricci R, Maggiano N, Vecchio FM, Gasbarrini G. Immunohistochemical analysis of ZO-1 in the duodenal mucosa of patients with untreated and treated celiac disease. *Digestion.* (2002) 65:227–33. doi: 10.1159/000063817
265. Perry I, Tselepis C, Hoyland J, Iqbal TH, Scott D, Sanders A, et al. Reduced cadherin/catenin complex expression in celiac disease can be reproduced *in vitro* by cytokine stimulation. *Lab Invest.* (1999) 79:1489–99.
266. Schumann M, Siegmund B, Schulzke JD, Fromm M. Celiac disease: role of the epithelial barrier. *CMGH.* (2017) 3:150–62. doi: 10.1016/j.jcmgh.2016.12.006
267. Mishra A, Prakash S, Sreenivas V, Das TK, Ahuja V, Gupta SD, et al. Structural and functional changes in the tight junctions of asymptomatic and serology-negative first-degree relatives of patients with celiac disease. *J Clin Gastroenterol.* (2016) 50:551–60. doi: 10.1097/MCG.0000000000000436
268. Hunt KA, Zhernakova A, Turner G, Heap GAR, Franke L, Bruinenberg M, et al. Newly identified genetic risk variants for celiac disease related to the immune response. *Nat Genet.* (2008) 40:395–402. doi: 10.1038/ng.102
269. Wapenaar MC, Monsuur AJ, Van Bodegraven AA, Weersma RK, Bevova MR, Linskens RK, et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. *Gut.* (2008) 57:463–7. doi: 10.1136/gut.2007.133132
270. Monsuur AJ, Bakker PIWD, Alizadeh BZ, Zhernakova A, Bevova MR, Strengman E, et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. *Nat Genet.* (2005) 37:1341–4. doi: 10.1038/ng1680
271. Wolters VM, Alizadeh BZ, Weijerman ME, Zhernakova A, van Hoogstraten IMW, Mearin ML, et al. Intestinal barrier gene variants may not explain the increased levels of antigliadin antibodies, suggesting other mechanisms than altered permeability. *Hum Immunol.* (2010) 71:392–6. doi: 10.1016/j.humimm.2010.01.016
272. Kumar V, Gutierrez-Achury J, Kanduri K, Almeida R, Hrdlickova B, Zhernakova D V., et al. Systematic annotation of celiac disease loci refines pathological pathways and suggests a genetic explanation for increased interferon-gamma levels. *Hum Mol Genet.* (2015) 24:397–409. doi: 10.1093/hmg/ddu453
273. Almeida R, Ricanõ-Ponce I, Kumar V, Deelen P, Szperl A, Trynka G, et al. Fine mapping of the celiac disease-associated LPP locus reveals a potential functional variant. *Hum Mol Genet.* (2014) 23:2481–9. doi: 10.1093/hmg/ddt619
274. Ciccocioppo R, Panelli S, Bellocchi MCC, Cangemi GC, Frulloni L, Capelli E, et al. The transcriptomic analysis of circulating immune cells in a celiac family unveils further insights into disease pathogenesis. *Front Med.* (2018) 5:182. doi: 10.3389/fmed.2018.00182
275. Dolfini E, Roncoroni L, Elli L, Fumagalli C, Colombo R, Ramponi S, et al. Cytoskeleton reorganization and ultrastructural damage induced by gliadin in a three-dimensional *in vitro* model. *World J Gastroenterol.* (2005) 11:7597–601. doi: 10.3748/wjg.v11.i48.7597

276. Strobel S, Brydon WG, Ferguson A. Cellobiose/mannitol sugar permeability test complements biopsy histopathology in clinical investigation of the jejunum. *Gut*. (1984) 25:1241–6. doi: 10.1136/gut.25.11.1241
277. Gass J, Bethune MT, Siegel M, Spencer A, Khosla C. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. *Gastroenterology*. (2007) 133:472–80. doi: 10.1053/j.gastro.2007.05.028
278. Pinier M, Verdu EF, Nasser-Eddine M, David CS, Vézina A, Rivard N, et al. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. *Gastroenterology*. (2009) 136:288–98. doi: 10.1053/j.gastro.2008.09.016
279. Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. *Aliment Pharmacol Ther*. (2007) 26:757–66. doi: 10.1111/j.1365-2036.2007.03413.x
280. Kelly CP, Green PHR, Murray JA, Dimarino A, Colatrella A, Leffler DA, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. *Aliment Pharmacol Ther*. (2013) 37:252–62. doi: 10.1111/apt.12147
281. Leffler DA, Kelly CP, Abdallah HZ, Colatrella AM, Harris LA, Leon F, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. *Am J Gastroenterol*. (2012) 107:1554–62. doi: 10.1038/ajg.2012.211
282. Leffler DA, Kelly CP, Green PHR, Fedorak RN, Dimarino A, Perrow W, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. *Gastroenterology*. (2015) 148:1311–9.e6. doi: 10.1053/j.gastro.2015.02.008
283. Hujoel IA, Murray JA. Refractory celiac disease. *Curr Gastroenterol Rep*. (2020) 22:1–8. doi: 10.1007/s11894-020-0756-8
284. Jauregi-Miguel A. The tight junction and the epithelial barrier in coeliac disease. *Int Rev Cell Mol Biol*. (2021) 358:105–32. doi: 10.1016/bs.ircmb.2020.09.010
285. Pearson ADJ, Eastham EJ, Laker MF, Craft AW, Nelson R. Intestinal permeability in children with Crohn's disease and Coeliac disease. *Br Med J*. (1982) 285:20–21. doi: 10.1136/bmj.285.6334.20
286. Ukabam SO, Clamp JR, Cooper BT. Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. *Digestion*. (1983) 27:70–4. doi: 10.1159/000198932
287. Abraham C, Cho JH. Mechanisms of inflammatory Bowel disease. *N Engl J Med*. (2009) 361:2066–78. doi: 10.1056/NEJMra0804647
288. Miner-Williams WM, Moughan PJ. Intestinal barrier dysfunction: implications for chronic inflammatory conditions of the bowel. *Nutr Res Rev*. (2016) 29:40–59. doi: 10.1017/S0954422416000019
289. Khan MW, Kale AA, Bere P, Vajjala S, Gounaris E, Pakanati KC. Microbes, intestinal inflammation and probiotics. *Expert Rev Gastroenterol Hepatol*. (2012) 6:81–94. doi: 10.1586/egh.11.94
290. Ingersoll SA, Ayyadurai S, Charania MA, Laroui H, Yan Y, Merlin D. The role and pathophysiological relevance of membrane transporter *pept1* in intestinal inflammation and inflammatory bowel disease. *Am J Physiol Gastrointest Liver Physiol*. (2012) 302:G484–92. doi: 10.1152/ajpgi.00477.2011
291. Dalmasso G, Nguyen HTT, Charrier-Hisamuddin L, Yan Y, Laroui H, Demoulin B, et al., Merlin D. *PepT1* mediates transport of the proinflammatory bacterial tripeptide L-Ala- γ -D-Glu-meso-DAP in intestinal epithelial cells. *Am J Physiol Gastrointest Liver Physiol*. (2010) 299:687–96. doi: 10.1152/ajpgi.00527.2009
292. Jappar D, Hu Y, Smith DE. Effect of dose escalation on the *in vivo* oral absorption and disposition of glycy sarcosine in wild-type and *Pept1* knockout mice. *Drug Metab Dispos*. (2011) 39:2250–7. doi: 10.1124/dmd.111.041087
293. De Medina FS, Daddaoua A, Requena P, Capitán-Cañadas F, Zarzuelo A, Dolores Suárez M, et al. New insights into the immunological effects of food bioactive peptides in animal models of intestinal inflammation. *Proc Nutr Soc*. (2010) 69:454–62. doi: 10.1017/S0029665110001783
294. Nässl AM, Rubio-Aliaga I, Sailer M, Daniel H. The intestinal peptide transporter *pept1* is involved in food intake regulation in mice fed a high-protein diet. *PLoS ONE*. (2011) 6:e0026407. doi: 10.1371/journal.pone.0026407
295. Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. *PLoS ONE*. (2011) 6:e0025637. doi: 10.1371/journal.pone.0025637
296. Chia-Hui Y. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease: RSM Library Discovery Service. *J Biomed Sci*. (2018) 25:79. doi: 10.1186/s12929-018-0483-8
297. Gruber L, Licht P, Rath E, Haller D. Nutrigenomics and nutrigenetics in inflammatory bowel diseases. *J Clin Gastroenterol*. (2012) 46:735–47. doi: 10.1097/MCG.0b013e31825ca21a
298. Ananthakrishnan AN, Bernstein CN, Iliopoulos D, Macpherson A, Neurath MF, Ali RAR, et al. Environmental triggers in IBD: a review of progress and evidence. *Nat Rev Gastroenterol Hepatol*. (2018) 15:39–49. doi: 10.1038/nrgastro.2017.136
299. Ho SM, Lewis JD, Mayer EA, Plevy SE, Chuang E, Rappaport SM, et al. Challenges in IBD research: environmental triggers. *Inflamm Bowel Dis*. (2019) 25:S13–23. doi: 10.1093/ibd/izz076
300. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. *Mayo Clin Proc*. (2006) 81:1462–71. doi: 10.4065/81.11.1462
301. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. *Dig Dis Sci*. (1989) 34:1841–54. doi: 10.1007/BF01536701
302. Higuchi LM, Khalili H, Chan AT, Richter JM, Bousvaros A, Fuchs CS. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. *Am J Gastroenterol*. (2012) 107:1399–406. doi: 10.1038/ajg.2012.196
303. Pedersen KM, Çolak Y, Vedel-Krogh S, Kobylecki CJ, Bojesen SE, Nordestgaard BG. Risk of ulcerative colitis and Crohn's disease in smokers lacks causal evidence. *Eur J Epidemiol*. (2021) 10.1007/s10654-021-00763-3. doi: 10.1007/s10654-021-00763-3
304. Singh UP, Singh NP, Murphy EA, Price RL, Fayad R, Nagarkatti M, et al. Chemokine and cytokine levels in inflammatory bowel disease patients. *Cytokine*. (2016) 77:44–9. doi: 10.1016/j.cyt.2015.10.008
305. Ostaff MJ, Stange EF, Wehkamp J. Antimicrobial peptides and gut microbiota in homeostasis and pathology. *EMBO Mol Med*. (2013) 5:1465–83. doi: 10.1002/emmm.201201773
306. Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjöberg J, Amir E, et al. Enteric defensins are essential regulators of intestinal microbial ecology. *Nat Immunol*. (2010) 11:76–83. doi: 10.1038/ni.1825
307. Peyrin-Biroulet L, Beisner J, Wang G, Nuding S, Oommen ST, Kelly D, et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. *Proc Natl Acad Sci USA*. (2010) 107:8772–7. doi: 10.1073/PNAS.0905745107
308. Wehkamp J, Harder J, Weichenthal M, Mueller O, Herrlinger KR, Fellermann K, et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. *Inflamm Bowel Dis*. (2003) 9:215–23. doi: 10.1097/00054725.200307000-00001
309. Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. *Cmgh*. (2017) 4:33–46. doi: 10.1016/j.jcmgh.2017.03.007
310. Courth LE, Ostaff MJ, Mailänder-Sánchez D, Malek NP, Stange EF, Wehkamp J. Crohn's disease-derived monocytes fail to induce Paneth cell defensins. *Proc Natl Acad Sci USA*. (2015) 112:14000–5. doi: 10.1073/pnas.1510084112
311. Wehkamp J, Koslowski M, Wang G, Stange EF. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. *Mucosal Immunol*. (2008) 1:67–74. doi: 10.1038/mi.2008.48
312. Paone P, Cani PD. Mucus barrier, mucins and gut microbiota: the expected slimy partners? *Gut*. (2020) 69:2232–43. doi: 10.1136/gutjnl-2020-322260
313. Van Der Post S, Jabbar KS, Birchenough G, Arike L, Akhtar N, Sjøvall H, et al. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. *Gut*. (2019) 68:2142–51. doi: 10.1136/gutjnl-2018-317571
314. Johansson ME, Ambort D, Pelaseyed T, Schütte A, Gustafsson JK, Ermund A, et al. Composition and functional role of the mucus layers in the intestine. *Cell Mol Life Sci*. (2011) 68:3635–41. doi: 10.1007/S00018-011-0822-3

315. Cornick S, Tawiah A, Chadee K. Roles and regulation of the mucus barrier in the gut. *Tissue Barriers*. (2015) 3:e982426. doi: 10.4161/21688370.2014.982426
316. Vivinus-Nébot M, Frin-Mathy G, Bziouche H, Dainese R, Bernard G, Anty R, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. *Gut*. (2014) 63:744–52. doi: 10.1136/gutjnl-2012-304066
317. Hollander D, Vadheim CM, Brettholz E, Peterson GM, Delahunty T, Rotter J. Increased intestinal permeability in patients with Crohn's disease and their relatives. *Ann Intern Med*. (1986) 105:883–5.
318. Arnott IDR, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. *Scand J Gastroenterol*. (2000) 35:1163–9. doi: 10.1080/003655200750056637
319. Wyatt J, Vogelsang H, Hübl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. *Lancet*. (1993) 341:1437–9. doi: 10.1016/0140-6736(93)90882-H
320. Arrieta MC, Bistriz L, Meddings JB. Alterations in intestinal permeability. *Gut*. (2006) 55:1512–20. doi: 10.1136/gut.2005.085373
321. Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, Fedorak RN. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. *Inflamm Bowel Dis*. (1999) 5:262–70. doi: 10.1097/00054725-199911000-00004
322. Reuter BK, Pizarro TT. Mechanisms of tight junction dysregulation in the SAMPIYitFc model of Crohn's disease-like ileitis. *Ann N Y Acad Sci*. (2009) 1165:301–7. doi: 10.1111/j.1749-6632.2009.04035.x
323. Su L, Shen L, Clayburgh DR, Nalle SC, Sullivan EA, Jon B, et al. Activation and contributes to development of experimental colitis. *Gastroenterology*. (2010) 136:551–63. doi: 10.1053/j.gastro.2008.10.081
324. Blair SA, Kane S V., Clayburgh DR, Turner JR. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. *Lab Invest*. (2006) 86:191–201. doi: 10.1038/labinvest.3700373
325. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening Baucke V, Ortner M, et al. Mucosal flora in inflammatory bowel disease. *Gastroenterology*. (2002) 122:44–54. doi: 10.1053/gast.2002.30294
326. Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, MacDonald TT, et al. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. *Lab Invest*. (2005) 85:1139–62. doi: 10.1038/labinvest.3700316
327. Ménard S, Cerf-Bensussan N, Heyman M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. *Mucosal Immunol*. (2010) 3:247–59. doi: 10.1038/mi.2010.5
328. Oshima T, Laroux FS, Coe LL, Morise Z, Kawachi S, Bauer P, et al. Interferon- γ and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. *Microvasc Res*. (2001) 61:130–43. doi: 10.1006/mvre.2000.2288
329. Albert-Bayo M, Paracuellos I, González-Castro AM, Rodríguez-Urrutia A, Rodríguez-Lagunas MJ, Alonso-Cotoner C, et al. Intestinal mucosal mast cells: key modulators of barrier function and homeostasis. *Cells*. (2019) 8:135. doi: 10.3390/cells8020135
330. Al-Sadi R, Ye D, Boivin M, Guo S, Hashimi M, Ereifej L, et al. Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway. *PLoS ONE*. (2014) 9:e0085345. doi: 10.1371/journal.pone.0085345
331. Gassler N, Rohr C, Schneider A, Kartenbeck J, Bach A, Obermüller N, et al. Inflammatory bowel disease is associated with changes of enterocytic junctions. *Am J Physiol Gastrointest Liver Physiol*. (2001) 281:216–28. doi: 10.1152/ajpgi.2001.281.1.g216
332. Shih DQ, Michelsen KS, Barrett RJ, Biener-Ramanujan E, Gonsky R, Zhang X, et al. Insights into TL1A and IBD pathogenesis. *Adv Exp Med Biol*. (2011) 691:279–88. doi: 10.1007/978-1-4419-6612-4_29
333. Cooney R, Jewell D. The genetic basis of inflammatory bowel disease. *Dig Dis*. (2009) 27:428–42. doi: 10.1159/000234909
334. Ishihara S, Aziz MM, Yuki T, Kazumori H, Kinoshita Y. Inflammatory bowel disease: review from the aspect of genetics. *J Gastroenterol*. (2009) 44:1097–108. doi: 10.1007/s00535-009-0141-8
335. Mayer L. Evolving paradigms in the pathogenesis of IBD. *J Gastroenterol*. (2010) 45:9–16. doi: 10.1007/s00535-009-0138-3
336. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature*. (2001) 411:599–603. doi: 10.1038/35079107
337. Kosovac K, Brenmoehl J, Holler E, Falk W, Schoelmerich J, Hausmann M, et al. Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients. *Inflamm Bowel Dis*. (2010) 16:1311–21. doi: 10.1002/ibd.21223
338. Rosenstiel P, Sebrier S. NOD-like receptors-pivotal guardians of the immunological integrity of barrier organs. *Adv Exp Med Biol*. (2009) 653:35–47. doi: 10.1007/978-1-4419-0901-5_3
339. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. *J Biol Chem*. (2003) 278:8869–72. doi: 10.1074/jbc.C200651200
340. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. *J Biol Chem*. (2003) 278:5509–12. doi: 10.1074/jbc.C200673200
341. Rosenstiel P, Fantini M, Bräutigam K, Kühbacher T, Waetzig GH, Seeger D, et al. TNF- α and IFN- γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. *Gastroenterology*. (2003) 124:1001–9. doi: 10.1053/gast.2003.50157
342. Buhner S, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? *Gut*. (2006) 55:342–7. doi: 10.1136/gut.2005.065557
343. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. *Semin Immunopathol*. (2015) 37:47–55. doi: 10.1007/s00281-014-0454-4
344. Fukata M, Arditi M. The role of pattern recognition receptors in intestinal inflammation. *Mucosal Immunol*. (2013) 6:451–63. doi: 10.1038/mi.2013.13
345. Zeuthen LH, Fink LN, Frokiaer H. Epithelial cells prime the immune response to an array of gut-derived commensals towards a tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor- β . *Immunology*. (2008) 123:197–208. doi: 10.1111/j.1365-2567.2007.02687.x
346. Rimoldi M, Chieppa M, Salucci V, Avogadri F, Sonzogni A, Sampietro GM, et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. *Nat Immunol*. (2005) 6:507–14. doi: 10.1038/ni1192
347. Travis S, Menzies I. Intestinal permeability: functional assessment and significance. *Clin Sci*. (1992) 82:471–88. doi: 10.1042/cs0820471
348. Bjarnason I, Macpherson A, Hollander D. Intestinal permeability: an overview. *Gastroenterology*. (1995) 108:1566–81. doi: 10.1016/0016-5085(95)90708-4
349. Wehkamp J, Stange EF. Paneth's disease. *J Crohn's Colitis*. (2010) 4:523–31. doi: 10.1016/j.crohns.2010.05.010
350. Khoshbin K, Camilleri M. Effects of dietary components on intestinal permeability in health and disease. *Am J Physiol Gastrointest Liver Physiol*. (2020) 319:G589–608. doi: 10.1152/AJPGI.0024.5.2020
351. Camilleri M. Human intestinal barrier: effects of stressors, diet, prebiotics, and probiotics. *Clin Transl Gastroenterol*. (2021) 12:e00308. doi: 10.14309/ctg.000000000000308
352. Klimberg VS, Souba WW. The importance of intestinal glutamine metabolism in maintaining a healthy gastrointestinal tract and supporting the body's response to injury and illness. *Surg Annu*. (1990) 22:61–76.
353. Zhou YP, Jiang ZM, Sun YH, Wang XR, Ma EL, Wilmore D. The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns: a randomized, double-blind, controlled clinical trial. *J Parenter Enter Nutr*. (2003) 27:241–5. doi: 10.1177/0148607103027004241
354. Peng X, Yan H, You Z, Wang P, Wang S. Effects of enteral supplementation with glutamine granules on intestinal mucosal barrier function in severe burned patients. *Burns*. (2004) 30:135–9. doi: 10.1016/j.burns.2003.09.032
355. Zhou QQ, Verne ML, Fields JZ, Lefante JJ, Basra S, Salameh H, et al. Randomised placebo-controlled trial of dietary glutamine

- supplements for postinfectious irritable bowel syndrome. *Gut*. (2019) 68:996–1002. doi: 10.1136/gutjnl-2017-315136
356. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. *Am J Clin Nutr*. (2008) 88:491–9S. doi: 10.1093/ajcn/88.2.491s
357. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. *Am J Physiol Gastrointest Liver Physiol*. (2007) 294:G208–16. doi: 10.1152/ajpgi.00398.2007
358. Hewison M. Vitamin D and innate and adaptive immunity. *Vitam Horm*. (2011) 86:23–62. doi: 10.1016/B978-0-12-386960-9.00002-2
359. Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. *BMC Immunol*. (2007) 8:5. doi: 10.1186/1471-2172-8-5
360. Zhao H, Zhang H, Wu H, Li H, Liu L, Guo J, et al. Protective role of 1,25(OH)₂vitamin D₃ in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. *BMC Gastroenterol*. (2012) 12:57. doi: 10.1186/1471-230X-12-57
361. Guzman-Prado Y, Samson O, Segal JP, Limdi JK, Hayee B. Vitamin D therapy in adults with inflammatory bowel disease: a systematic review and meta-analysis. *Inflamm Bowel Dis*. (2020) 26:1819–30. doi: 10.1093/ibd/izaa087
362. Raftery T, Martineau AR, Greiller CL, Ghosh S, McNamara D, Bennett K, et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: results from a randomised double-blind placebo-controlled study. *United Eur Gastroenterol J*. (2015) 3:294–302. doi: 10.1177/2050640615572176
363. Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MAR. Regulation of immune cell function by short-chain fatty acids. *Clin Transl Immunol*. (2016) 5:e73. doi: 10.1038/cti.2016.17
364. Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, De los Reyes-Gavilán CG, Salazar N. Intestinal short chain fatty acids and their link with diet and human health. *Front Microbiol*. (2016) 7:185. doi: 10.3389/fmicb.2016.00185
365. Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, et al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. *Appl Environ Microbiol*. (2000) 66:1654–61. doi: 10.1128/AEM.66.4.1654-1661.2000
366. Louis P, Young P, Holtrop G, Flint HJ. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. *Environ Microbiol*. (2010) 12:304–14. doi: 10.1111/j.1462-2920.2009.02066.x
367. Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. *MBio*. (2014) 5:e00889. doi: 10.1128/mBio.00889-14
368. Kannampalli P, Shaker R, Sengupta JN. Colonic butyrate-algesic or analgesic? *Neurogastroenterol Motil*. (2011) 23:975–9. doi: 10.1111/j.1365-2982.2011.01775.x
369. Banasiewicz T, Krokowicz, Stojcev Z, Kaczmarek BF, Kaczmarek E, Maik J, et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. *Color Dis*. (2013) 15:204–9. doi: 10.1111/j.1463-1318.2012.03152.x

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Barbara, Barbaro, Fuschi, Palombo, Falangone, Cremon, Marasco and Stanghellini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.